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It is the intrinsic tone of the vascular smooth
muscle that ultimately modulates vasomotor tone.
Increases in vasomotor tone contribute to patho-
logic states (such as vasospasm and hypertension)
although decreases in tone can lead to circulatory
collapse. The tone in vascular smooth muscle is a
balance between factors that initiate contractile sig-
naling pathways and relaxation pathways.
The signaling events that have been implicated in
the initiation of smooth muscle contraction include
increases in intracellular Ca2+ and activation of the
Ca2+ calmodulin–dependent myosin light chain
kinase, which leads to increases in the phosphoryla-
tion of myosin light chains.1,2 However, numerous
investigators have demonstrated that there is no sim-
ple correlation between the extent of myosin light
chain phosphorylation and/or intracellular Ca2+
concentrations and the state of contraction or relax-
ation of vascular smooth muscles.3-6 Thus mecha-
nisms other than myosin light chain phosphoryla-
tion and/or intracellular Ca2+ concentrations may
regulate the contractile state of smooth muscles.
Many investigators have implicated a kinase cas-
cade involving protein kinase C and activation of
mitogen-activated protein kinase (MAPK) in the
sustained phase of vascular smooth muscle.7-9 We
have recently demonstrated that agonist-induced
smooth muscle contraction is associated with
increases in the tyrosine phosphorylation of both
MAPK and a stress-activated protein kinase.10-12
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Activation of p38 stress-activated protein kinase
leads to increases in the phosphorylation of heat
shock protein (HSP) 27 in smooth muscle.13-15 The
addition of anti-HSP27 antibodies to permeabilized
intestinal smooth muscles inhibits the bombesin-
induced contraction of these muscles.16 These data
suggest that increases in the phosphorylation of
HSP27 are associated with smooth muscle contrac-
tion and that phosphorylated HSP27 may modulate
smooth muscle contraction.
Alternate signaling pathways modulate smooth
muscle relaxation. Nitric oxide and nitrosovasodila-
tors relax vascular smooth muscle by activating
guanylate cyclase, leading to increases in cyclic
guanosine monophosphate (cGMP) and activation
of cGMP-dependent protein kinase.17 Isoproterenol
and prostacyclin relax vascular smooth muscle by
activating adenylate cyclase, leading to increases in
cyclic adenosine monophosphate (cAMP) and acti-
vation of cAMP-dependent protein kinase (PKA).18
A major phosphorylation event that occurs with acti-
vation of either cGMP-dependent protein kinase or
PKA is an increase in the phosphorylation of the
small heat shock-related protein, HSP20.19,20
Endothelial-dependent vasorelaxation is also associ-
ated with increases in the phosphorylation of
HSP20.21 Increases in the phosphorylation of
HSP20 do not occur in umbilical artery smooth
muscle, which is uniquely refractory to cyclic
nucleotide-dependent vasorelaxation.22-24 Finally,
the introduction of phosphopeptide analogues of
HSP20 inhibits serotonin-induced contractions.25
Taken together, these data support a role for HSP20
in the mediation of cyclic nucleotide-dependent
vasorelaxation.
HSPs represent a family of phylogenetically well-
conserved proteins whose expression can be induced
by cellular stress, thus they are often termed stress pro-
teins. Thermal stress, chemical stress, osmotic stress,
oxidative stress, and mechanical stress can all induce
HSP expression. For example, arsenite is a metabolic
toxin that induces cell injury and is commonly used
to induce HSP expression in cultured cells. Many
HSPs are also expressed constitutively and thus
appear to play a role in normal cellular behavior.
Although the precise functions of the small HSPs are
not known, many HSPs act as “molecular chaper-
ones,” assisting in the assembly, disassembly, stabi-
lization, and internal transport of intracellular pro-
teins. There is increasing evidence of a role for HSPs
in vascular diseases such as hypertension. Stress-
induced hypertension in rats leads to the increased
expression of HSP70 and HSP27, specifically in vas-
cular and adrenal tissues.26 The cellular response to
surgical stress also involves the induction of HSPs,
again localized to vascular and adrenal tissues.27 The
two small HSPs, HSP20 and HSP27, coexist in
macromolecular aggregates and are highly expressed
in muscle tissues.19,28 Thus the two small HSPs may
be associated late-phase signaling molecules that reg-
ulate smooth muscle contraction and/or relaxation
responses. The localization of the stress response to
vascular tissue and the association of stress with alter-
ations in vasomotor tone also implicate stress proteins
in the modulation of vascular tone.
In this investigation, we hypothesized that the
exposure of intact vascular smooth muscle to cellu-
lar stress would be associated with changes in the
phosphorylation state of the small HSPs. In addi-
tion, alterations in the phosphorylation of the small
HSPs would be associated with changes in the con-
traction and/or relaxation of the muscles.
MATERIAL AND METHODS
Materials. HEPES was obtained from American
Bioanalytical (Natick, Mass). Urea, sodium dodecyl-
sulfate (SDS), glycine, and tris-(hydroxymethyl)
aminomethane (Tris) were obtained from Research
Organics (Cleveland, Ohio). Coomassie brilliant
blue was obtained from ICN Biomedicals Inc
(Aurora, Ohio). [γ-32P]-adenosine triphosphate,
32P-orthophosphate, 125I-protein A, 125I-protein G,
and antibodies against the inducible form of HSP70
were obtained from Amersham (Arlington Heights,
Ill). Forskolin and SB203580 were obtained from
Calbiochem (La Jolla, Calif). Piperazine diacry-
lamide and other electrophoresis reagents were
obtained from Biorad (Hercules, Calif). The 3-([3-
cholamidopropyl dimethylammonio]-1-propanesul-
fonate (CHAPS), ethylene glycol-bis(β-aminoethyl
ether)-N,N,N´N´-tetraacetic acid, ethylenediamin-
etetraacetic acid, polyoxyethylene-sorbitan mono-
laurate (Tween-20), and all other reagent-grade
chemicals were obtained from Sigma Chemical Co (St
Louis, Mo). Antibodies against HSP27 were obtained
from Dr Michael Welsh (Ann Arbor, Mich),29 and
antibodies against HSP20 were obtained from Dr
Kanefusa Kato (Aichi, Japan).19 Donkey anti-mouse
and goat anti-rabbit secondary antibodies were
obtained from Jackson Immunochemical (West
Grove, Pa). MAPKAP kinase II was purchased from
Upstate Biotechnology (Lake Placid, NY), and
recombinant HSP27 was purchased from StressGen
(Victoria, British Colombia, Canada).
Physiologic contractile responses. Bovine
carotid arteries were dissected from fetal calves at a
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local abattoir (Shapiro’s, Augusta, Ga) and placed
directly in cold HEPES buffer (140 mmol/L NaCl,
4.7 mmol/L potassium chloride, 1.0 mmol/L
MgSO4, 1.0 mmol/L NaH2PO4, 1.5 mmol/L CaCl2,
10 mmol/L glucose, and 10 mmol/L HEPES; pH
7.4). The carotid vessels were dissected free from the
adventitia and were opened longitudinally. The
endothelium was removed by rubbing the intima with
a cotton-tipped applicator. Complete denudation of
endothelial cells with this technique has been previous-
ly confirmed with scanning electron microscopy.30
Transverse strips, 1.0 mm in width, were cut, and each
end was tied to a loop of 3-0 silk. The tissue was sus-
pended in a muscle bath containing bicarbonate buffer
(120 mmol/L NaCl, 4.7 mmol/L potassium chloride,
1.0 mmol/L MgSO4, 1.0 mmol/L NaH2PO4, 10
mmol/L glucose, 1.5 mmol/L CaCl2, and 25
mmol/L Na2HCO3; pH 7.4), equilibrated with 95%
oxygen/5% carbon dioxide at 37°C. The strips were
fixed at one end to a stainless steel wire and attached to
a force transducer (TRN001; Kent Scientific,
Litchfield, Conn) interfaced with a Data Translation A-
D board (DT2801; Data Translation, Inc, Marlboro,
Mass). Data were acquired with Daisylab software
(Daisytec, Amherst, NH).
Experimental protocols. The strips were equi-
librated in bicarbonate buffer at 1 g of tension for 2
hours. The strips were then progressively stretched,
and the isometric force was generated in response
to 110 mmol/L potassium chloride (with equimo-
lar replacement of NaCl in bicarbonate buffer)
determined until the maximal force was produced.
The muscles were then treated with the following
experimental protocols: (1) equilibration in buffer
alone (control); (2) sodium arsenite (0.5 mmol/L)
for 30 minutes followed by equilibration in buffer
for 2 hours (arsenite); (3) equilibrated in buffer at
41°C for 30 minutes and then equilibrated at 37°C
for 2 hours (heat shock); (4) SB203580 (100
µmol/L) for 15 minutes and then sodium arsenite
(0.5 mmol/L) for 30 minutes, washed 3 times in
buffer; SB203580 (100 µmol/L) was re-added, and
the strips were equilibrated for 2 hours (SB/arsen-
ite); (5) SB203580 (100 µmol/L) for 2 hours and
30 minutes (SB). The strips were then treated with
serotonin (10–6 mmol) for 10 minutes followed by
forskolin (10–5 mmol) for 10 minutes or sodium
nitroprusside (10–7 mmol and 10–6 mmol) for 10
minutes. Agonists and inhibitors were added direct-
ly to the muscle bath; the indicated concentrations
represent the final concentration of the agonist or
inhibitors in the bath.
Peptide synthesis. Peptide synthesis was con-
ducted on a peptide synthesizer (Model 433A;
Applied Biosystems, Farmington, Mass) with stan-
dard Fmoc chemistry. The synthesis of the phos-
phopeptides involved an increase in coupling times
of 20 minutes. The phosphorylated amino acid
derivatives were purchased from Calbiochem-
Novabiochem (La Jolla, Calif). Peptide purity was
determined by high-performance liquid chromotog-
raphy. Phosphopeptides were analyzed by mass spec-
trometry.
Production and affinity purification of phos-
phorylation state specific antibodies. The synthet-
ic peptide, VAAPAYSRALSRQLS (S denotes phos-
phoserine corresponding to serines 78 and 82 on
HSP27,31 conjugated to keyhole limpet hemocyanin
(0.5 mg) was injected subcutaneously into two rab-
bits in collaboration with Berkley Antibody
Company (Berkley, Calif). The rabbit serum was
tested with an enzyme-linked immunosorbent assay
with the use of the synthetic peptide. A titer that
extinguished at a dilution of 1:10,000 was obtained
and was affinity purified with the use of the
AminoLink Plus Immobilization Kit (Pierce,
Rockford, Ill). In brief, the rabbit serum was cen-
trifuged at 100,000g for 30 minutes at 4°C. The
columns were prepared according to the manufac-
turer’s directions with 10 mg of the phosphorylated
HSP27 peptide. The rabbit sera (5 mL) was added
to the phosphorylated peptide column and was incu-
bated at room temperature for 1 hour. The column
was incubated for 1 hour, washed with phosphate-
buffered saline solution (PBS; 10 mmol/L phos-
phate, pH 7.5, 0.15 mmol NaCl), and eluted with
20 mL of 100 mmol/L glycine, pH 2.5. Fractions
(1 mL) were collected and neutralized with 50 µL of
sodium phosphate buffer, pH 8.0. The fractions
were analyzed in a spectrophotometer; the 280-nm
peak fractions were dialyzed against PBS, and the
optimal dilution (1:2000) and protein loading (30
µg) for immunoblotting were determined.
Immunoblotting. Proteins were separated on
15% SDS-polyacrylamide gel electrophoresis
(PAGE) gels32 and transferred to Immobilon
(Millipore, Bedford, Ga) for 210 volt hours. The
blots were air dried and subsequently blocked with
Tris-buffered saline solution (TBS; 10 mmol/L Tris,
150 mmol/L NaCl, pH 7.4)/5% milk for 1 hour.
The blots were then incubated with anti-HSP27
antibodies in TBS/milk overnight at 4°C. The blots
were washed three times (5 minutes each) in
TBS/Tween-20 (0.5%). Immunoreactive protein
was determined with the use of 125I-protein A or
enhanced chemiluminescence (DuPont NEN,
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Boston, Mass). The blots were again washed six
times (5 minutes each) in TBS/Tween-20 and
exposed on PhosphorImager screens (Molecular
Dynamics, Sunnyvale, Calif) or x-ray film.
Whole cell phosphorylation. Strips of bovine
carotid artery smooth muscle were incubated in 150
µCi/mL 32P-orthophosphate in 10 mmol/L HEPES
(pH 7.4), 150 mmol/L NaCl, 4.7 mmol/L potassium
chloride, 1.0 mmol/L MgSO4, 1.0 mmol/L
NaH2PO4, 10 mmol/L glucose, 1.5 mmol/L CaCl2,
and 25 mmol/L Na2HCO3, oxygenated with 95%
oxygen, 5% carbon dioxide, at 37°C, for 4 hours. The
muscle strips were then stimulated according to the
experimental protocols described earlier. The vessels
were snap frozen in liquid nitrogen, ground to a fine
powder with a mortar and pestle, and resuspended in
90% acetone, 10% trichloroacetic acid, 100 mmol/L
dithiothretol. The suspension was quickly frozen in
liquid nitrogen and allowed to slowly return to room
temperature. The suspension was centrifuged
(10,000g) and washed three times in acetone. The pel-
lets were dried under a stream of nitrogen and solubi-
lized in 9 mmol urea, 2% CHAPS, and 100 mmol/L
dithiothretol overnight at room temperature. The
samples were then adjusted to 9 mmol urea, 2%
CHAPS, 100 mmol/L dithiothretol, 15% glycerol,
and 5% ampholines (five parts 6-8, three parts 5-7, and
two parts 3-10). The proteins were separated on two-
dimensional gels.
Two-dimensional gel electrophoresis. Proteins
were separated by two-dimensional gel elec-
trophoresis by the method of O’Farrell33 that had
been modified by Hoschstrasser et al.34 In brief, 5 to
10 mg of protein was loaded onto 12-cm × 15-cm
slab isofocusing gels consisting of 4% acrylamide,
0.1% piperazine diacrylamide, 9 mmol urea, 5%
ampholines (five parts 6-8, three parts 5-7, and two
parts 3-10), and 2% CHAPS. Temed (0.04%) and
ammonium persulfate (0.1%) were used to initiate
polymerization. The cathode buffer consisted of 20
mmol/L sodium hydroxide and the anode buffer 10
mmol/L phosphoric acid. The proteins were
focused for 10,000 volt hours. The gels were fixed
in 10% trichloroacetic acid and stained overnight
with Neuhoff ’s Coomassie stain. The lanes of
stained proteins were cut from the isofocusing slab
gels and equilibrated in 10 mmol/L Tris (pH 6.8),
3% SDS, 19% ethanol, 4% β-mercaptoethanol, and
0.004% bromophenol blue for 10 minutes. The pro-
teins were then separated on 12% acrylamide SDS
gels and stained with Coomassie blue, and autoradio-
graphs were obtained. Equal protein loading was
confirmed by densitometric analysis of Coomassie
blue staining of actin. Some of the gels were trans-
ferred to Immobilon and probed with anti-HSP27
antibodies.
Immunohistochemistry. Strips of carotid arter-
ies were treated with the experimental protocols,
fixed in 4% formalin, and embedded in paraffin. Five
micron cross-sections were mounted on polylysine
slides. The slides were deparaffinized with xylene
and graded dilutions of ethanol. Endogenous perox-
idase was quenched with 3% hydrogen peroxide.
The sections were rinsed in PBS (10 mmol/L phos-
phate, pH 7.5, 0.15 mmol NaCl) and incubated
with the phosphorylation state–specific HSP27 anti-
bodies (1:100 dilution for 12 hours at 4°C). A
Vectastain Universal Quick Kit (Vector Labs,
Burlingame, Calif) was used to detect immunoreac-
tive protein according to the manufacturer’s recom-
mendations. The sections were counterstained with
Mayer’s hematoxylin and mounted.
Data analysis. Values are reported as mean ±
SEM. The statistical differences between the two
groups were determined with the Student t test and
between multiple groups with one-way repeated
measures analysis of variance with Sigma Stat soft-
ware (Jandel Scientific, San Rafeal, Calif). A proba-
bility value less than .05 was considered significant.
Densitometric analysis was performed on autoradio-
graphs and on immunoblots in which 125I-protein A
was the secondary antibody with a PhosphorImager
(Molecular Dynamics) and ImageQuant software
(Molecular Dynamics).
RESULTS
Physiologic responses to cellular stress.
Treatment of strips of bovine carotid artery smooth
muscle with sodium arsenite did not change basal ten-
sion (Fig 1) or the magnitude of the contractile
response to serotonin (Fig 1 and 2, A). Preincubation
of the strips with the inhibitor of the MAPKAP kinase
II pathway, SB203580 (100 µmol/L)35 also had no
effect on the magnitude of contractile responses to
serotonin (Fig 2, A). There was also no change in the
magnitude of the contractile response to high extra-
cellular potassium chloride (110 mmol/L) before and
after arsenite treatment (6.26 ± 1.0 g of tension vs 5.9
± 0.6 g of tension, respectively; n = 4 animals; P >
.05).
Treatment with sodium arsenite significantly
inhibited the relaxation responses of serotonin pre-
contracted muscles to the adenylate cyclase activator
forskolin (10–5 mmol; Fig 2, B). In muscles pre-
treated with SB203580, there was no inhibition of
forskolin-induced relaxation after arsenite treatment
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and characterized. The specificity of the affinity-
purified phosphorylation state–specific antibodies
for phosphorylated HSP27 was determined with
whole-cell phosphorylation of strips of bovine
carotid artery smooth muscle that were treated with
arsenite (0.5 mmol/L). The proteins were homoge-
nized, separated by two-dimensional electrophore-
sis, and transferred to Immobilon. Autoradiographs
were obtained, and the blots were then probed with
the phosphorylation state–specific HSP27 antibod-
ies (rabbit polyclonal antibodies with an anti-rabbit
secondary). The blots were washed in peroxide fol-
lowed by block buffer to remove the enhanced
chemiluminescence (ECL) and then incubated in
antibodies that recognize all isoforms of HSP27
(mouse monoclonal antibodies followed by an 
anti-mouse secondary).29 The phosphorylation
state–specific antibodies recognized all of the phos-
phorylated isoforms of HSP27 but not the non-
phosphorylated HSP27 (Fig 3).
Recombinant HSP27 was phosphorylated in
vitro by MAPKAP kinase II to determine the sensi-
tivity of the phosphorylation state–specific antibod-
ies. The proteins were separated by SDS-PAGE and
transferred to Immobilon; the blots were probed
with the phosphorylation state–specific HSP27 anti-
bodies. The phosphorylation state–specific antibod-
ies recognized 1.0 to 10 µg of phosphorylated
recombinant HSP27 in a linear fashion (Fig 4; the r2
of three separate experiments was 0.92). The non-
phosphorylated recombinant protein was not recog-
nized by the phosphorylation state–specific antibod-
ies (data not shown).
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Fig 1. Contractile responses of vascular smooth muscle after arsenite: Strips of vascular smooth
muscle were treated with the protocols described. Treatment of strips of bovine carotid artery
smooth muscle with sodium arsenite (As) did not change the basal tension of the strips. The
magnitude of the contractile response to serotonin (5HT; 10–6 mmol) and to potassium chlo-
ride (KCl; 110 mmol/L) was the same before and after arsenite treatment.
(Fig 2, B). Because activation of cAMP-dependent
and cGMP-dependent signaling pathways leads to
active relaxation of agonist-contracted muscles, the
relaxation responses to the guanylate cyclase activa-
tor, sodium nitroprusside (SNP) were determined
after arsenite treatment. Arsenite treatment signifi-
cantly inhibited the relaxation responses to 10–6
mmol sodium nitroprusside, (52.2% ± 4.6% relax-
ation after arsenite, compared with 84.3% ± 3.7%
relaxation in the control strips; n = 8 animals; P <
.05), and 10–7 mmol sodium nitroprusside (30.6% ±
4.3% relaxation after arsenite, compared with 60.9%
± 4.8% relaxation in the control strips; n = 8 animals;
P < .05). In muscles pretreated with SB203580,
there was no significant inhibition of sodium nitro-
prusside–induced relaxation after arsenite treatment
(data not shown).
These studies were performed with the chemical
stressor, sodium arsenite. Additional studies were
performed to determine if thermal stress or heat
shock would affect contraction and/or relaxation.
Heat shock did not alter basal tension or the magni-
tude of the contractile responses to serotonin or
high potassium chloride (data not shown). Heat
shock significantly inhibited the relaxation responses
to 10–7 mmol forskolin (12.2% ± 1.6% relaxation
after heat shock, compared with 32.04% ± 3.8%
relaxation in control strips; n = 8 animals; P < .05,
analysis of variance).
HSP phosphorylation after arsenite treat-
ment. To determine the effect of arsenite treatment
on the phosphorylation of HSP27, phosphorylation
state–specific anti-HSP27 antibodies were produced
The phosphorylation state–specific antibodies
were then used to quantitate the phosphorylation of
HSP27 after arsenite treatment. Arsenite treatment
led to an increase in the phosphorylation of HSP27
that was inhibited by pretreatment with SB203580
(Fig 5). With the use of an antibody that recognized
all isoforms of HSP27,29 there was no increase in the
amount of immunoreactive HSP27 protein after
arsenite treatment (26.7 ± 4.7 densitometric units
[control] vs 26.9 ± 5.8 densitometric units [arsen-
ite]; n = 6 animals; P > .05) or immunoreactive
HSP20 protein (7.2 ± 0.3 densitometric units [con-
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Fig 2. Cyclic nucleotide-dependent vasorelaxation is
impaired after arsenite treatment: Strips of vascular
smooth muscle were treated with the protocols described.
The contractile responses to serotonin (10–6 mmol) were
normalized to the initial high extracellular potassium chlo-
ride contraction (%KCl contraction, A) and the relaxation
responses to forskolin (10–5 mmol) were determined
based on the maximal contraction elicited by serotonin
(%relaxation, B). The strips were equilibrated in buffer
alone (C) or treated with arsenite (A), arsenite and
SB203580 (A/S), or SB203580 alone (S) as described in
the experimental protocols (n = 6-10 animals; *P < .05
compared with control).
Fig 3. Characterization of phosphorylation state–specific
antibodies: Strips of vascular smooth muscle were incu-
bated in the presence of 32P-[orthophosphate], treated
with arsenite (0.5 mmol) and homogenized. The proteins
were separated on two-dimensional gels and transferred
to Immobilon. An autoradiograph was obtained (A), and
the blots were probed with antibodies that recognize all
isoforms of HSP27 (B),29 followed by the phosphoryla-
tion-state specific antibodies (C). The different phosphor-
ylated isoforms of HSP27 (A, B, C, and D) and the non-
phosphorylated isoform (NP) are shown. The relative
mobility of the phosphorylated myosin light chains (m) is
shown in A.
A
B
A
B
C
trol] vs 7.6 ± 0.3 densitometric units [arsenite]; n = 4
animals; P > .05). There was also no significant
increase in the expression of the inducible form of
another HSP, HSP70, after arsenite treatment (33.0 ±
15.4 densitometric units [control] vs 28.5 ± 11.0
densitometric units [arsenite]; n = 6 animals; P > .05).
Cyclic nucleotide-dependent vasorelaxation is
associated with increases in the phosphorylation of
another HSP, HSP20.20 To determine whether the
impaired vasorelaxation after arsenite treatment was
associated with decreases in HSP20 phosphorylation,
whole cell phosphorylation and two-dimensional gel
electrophoresis were performed. Arsenite treatment
led to an increase in the phosphorylation of all three
proteins that have been previously identified as dif-
ferent isoforms of HSP2715 and a decrease in the
phosphorylation of two isoforms of HSP20 (Fig 6;
Table I). There was an increase in the phosphoryla-
tion of two proteins that have been previously iden-
tified as different isoforms of HSP2020 after forskolin
treatment (10–5 mmol) in both control and arsenite-
treated muscles. However, the increase in the phos-
phorylation of the most acidic isoform of HSP20
(isoform 8) after forskolin treatment was less in the
arsenite pretreated muscles (Table I).
Immunohistochemical analysis of HSP27
phosphorylation. Immunohistochemistry was per-
formed on strips of bovine carotid artery smooth
muscle to qualitatively confirm increases in the phos-
phorylation of HSP27 after arsenite treatment and to
localize the phosphorylated HSP27 in the blood ves-
sels. Immunoreactive phosphorylated HSP27 was
abundant in the medial smooth muscle cells of bovine
carotid arteries that had been treated with arsenite
(Fig 7). Most of the staining was perinuclear; howev-
er, phosphorylated HSP27 was also localized in focal
punctate areas in the cytoplasm of the muscles. There
was little immunoreactive phosphorylated HSP27
detected in untreated vessels or in muscles pretreated
with SB203580 (Fig 7). Incubation of the arsenite-
treated muscles with antibodies against phosphorylat-
ed HSP27 in the absence of the primary antibody (1
µmol/L) revealed no immunoreactive staining in the
arsenite-treated vessels (data not shown).
DISCUSSION
Recent data have implicated the small HSP,
HSP27, in mediating contractile events in intestinal,
tracheal, and vascular smooth muscles.13,14,16 In this
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Fig 4. Sensitivity of phosphorylation state–specific anti-
bodies: Recombinant HSP27 was phosphorylated in vitro
by MAPKAP kinase II. The proteins were separated by
SDS-PAGE and transferred to Immobilon. The blots were
probed with the phosphorylation state–specific HSP27
antibodies. The relative mobility of molecular weight
markers is on the left of the panel, and the amount of
recombinant HSP27 (in micrograms) is on the bottom.
Fig 5. Quantitation of HSP27 phosphorylation: Strips of
vascular smooth muscle were equilibrated in buffer alone
(C) or treated with arsenite (A), arsenite and SB203580
(A/S), or SB203580 alone (SB) as described in the exper-
imental protocols. The strips were homogenized, separat-
ed on SDS-PAGE gels, transferred to Immobilon, and
probed with the phosphorylation state specific antibodies
(A). The relative mobility of molecular weight markers is
shown to the left of A and of phosphorylated HSP27 by
the arrow. Densitometric analysis (relative densitometric
units) of multiple experiments is depicted in B (n = 6 ani-
mals; *P < .05, compared with control).
A
B
investigation, we demonstrate that an agent known
to induce cellular stress, sodium arsenite, led to sig-
nificant increases in the phosphorylation of HSP27
(Fig 5). These increases in the phosphorylation of
HSP27 were inhibited by an inhibitor of the MAP-
KAP kinase II pathway, SB203580 (Fig 5).35 The
increases in the phosphorylation of HSP27, induced
by arsenite treatment, were not associated with
increases in basal tone or the magnitude of contrac-
tion induced by the agonist, serotonin, or high-
extracellular potassium chloride (Figs 1 and 2).
Thus, although increases in the phosphorylation of
HSP27 are associated with agonist-induced vascular
smooth muscle contraction, increases in the phos-
phorylation of HSP27, induced by arsenite treat-
ment, were not associated with alterations in vascu-
lar smooth muscle contractile responses.
Cellular stress, induced by arsenite and heat
shock, led to the inhibition of cyclic nucleotide-
dependent relaxation (Fig 2). This impaired relax-
ation was not associated with increases in the
amount of immunoreactive HSP27 or the presence
of the inducible form of another HSP, HSP70, and
did not occur in muscles that were pretreated with
SB203580. These findings suggest that the effects of
arsenite treatment in this system were likely related
to increases in the phosphorylation of HSP27. One
of the phosphorylation events associated with cyclic
nucleotide-dependent relaxation of vascular smooth
muscle is an increase in the phosphorylation of
another small HSP, HSP20.20 Arsenite treatment led
to decreases in the phosphorylation of HSP20 and
inhibited cAMP-dependent phosphorylation of the
most acidic isoform of HSP20 (Fig 6; Table I).
Human umbilical artery smooth muscle from full-
term pregnancies is uniquely refractory to cyclic
nucleotide-dependent vasorelaxation.22 This impaired
relaxation is associated with an increased amount of
phosphorylated HSP27 in umbilical artery smooth
muscle36 and a lack of cyclic nucleotide-dependent
phosphorylation of HSP20.23 Thus increases in the
phosphorylation of HSP27 may inhibit relaxation by
inhibiting the phosphorylation of HSP20 in both vas-
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Fig 6. Whole cell phosphorylation: Strips of bovine
carotid artery smooth muscle were treated with buffer
alone (A), buffer alone followed by forskolin (B), arsenite
(0.5 mmol/L for 30 minutes followed by equilibration in
buffer for 2 hours; C), or arsenite (0.5 mmol/L for 30
minutes followed by equilibration in buffer for 2 hours)
followed by forskolin (10 µmol/L for 10 minutes; D).
HSP phosphorylation was quantitated with the use of
whole cell phosphorylation and two-dimensional elec-
trophoresis. The relative mobility of the myosin light
chains (m), the three phosphorylated isoforms of HSP27
(A, B, C), and the three phosphorylated isoforms of
HSP20 (8, 3, 4) are labeled on the blots. The relative
mobility of molecular weight markers is shown on the
right of each panel, and the isoelectric-focusing gradient is
shown on the top of A.
A
B
C
D
cular smooth muscle that has been exposed to chem-
ical stressors and under physiologic conditions in
which impaired cyclic nucleotide-dependent relax-
ation contributes to vasospasm.
HSP20 was first identified as a protein that co-
purified with HSP27.19 HSP20 and HSP27 coexist
in macromolecular aggregates.19 We have recently
determined that cyclic nucleotide-dependent phos-
phorylation of HSP20 leads to a redistribution of
the protein to a macromolecular aggregate that
elutes in a similar fraction from a molecular sieving
column as HSP27 and the regulatory myosin light
chains.29 In addition to an association with each
other and with one element of the contractile
machinery, the myosin light chains, there is evidence
that both HSP20 and HSP27 are associated with
actin.39,40 HSP27 has been implicated in modulat-
ing actin filament dynamics.40 Thus the functions of
the small HSPs may be interdependent and related
to phosphorylation and macromolecular associa-
tions. The small HSPs may alter contraction and/or
relaxation by directly interacting with and modifying
the interactions of specific elements the contractile
machinery.41
Acrocyanosis and the progression to peripheral
gangrene (black foot disease) have been associated
with arsenic ingestion, and the extent of disease is
related to the total dose of arsenic ingested.37
Increased vasospastic reactivity in the fingers in
smelter workers has been associated with functional
alterations in the vessels caused by inhalation of
arsenic.38 Thus arsenite, a metabolite of arsenic, may
lead to clinical vasospastic disorders in humans. The
data in this article provide potential molecular mech-
anisms by which arsenite may lead to vasospasm. In
addition, stress-induced hypertension is associated
with increases in the expression of HSP27 in the vas-
culature.26 Thus, although a putative role for the
small HSPs in hypertension is plausible, further
work is needed to determine whether the modula-
tion of vasomotor tone by HSPs is operative in
hypertension.
In summary, we demonstrated that treatment of
intact vascular smooth muscles with the chemical
stressor, sodium arsenite, leads to increases in the
phosphorylation of HSP27 without increasing the
amount of the HSP27 protein. Increases in the
phosphorylation of HSP27 did not alter resting tone
or the contractile response to agonists in vascular
smooth muscles. However, increases in the phos-
phorylation of HSP27 were associated with impaired
cyclic nucleotide-dependent relaxation. This
impaired vasorelaxation was also associated with
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Fig 7. Immunohistochemical analysis of HSP27 in arse-
nite-treated vascular smooth muscle: Strips of bovine
carotid artery smooth muscle were treated with buffer
alone (A), arsenite (0.5 mmol/L for 30 minutes followed
by equilibration in buffer for 2 hours; B), or SB203580
(100 µmol/L) for 15 minutes and then sodium arsenite
(0.5 mmol/L) for 30 minutes; the strips were washed
three times in buffer; SB203580 (100 µmol/L) was
added, and the strips were equilibrated for 2 hours (C;
original magnification, 63×). The strips were fixed and
stained with the affinity-purified phosphorylation
state–specific anti-HSP27 antibodies.
decreases in cyclic nucleotide-dependent phospho-
rylation of HSP20. Taken together, these data sug-
gest molecular mechanisms whereby cellular stress
may lead to the changes in vasomotor tone that
occur in pathologic settings such as vasospasm and
hypertension.
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